Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo R Zacharski

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Cancer Letters|August 17, 2002
Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathyLeo R Zacharski
Clinical Chemistry|September 13, 2014
Ferrotoxic disease: the next great public health challengeLeo R Zacharski
Clinical Chemistry|February 4, 2015
In replyLeo R Zacharski
Translational Lung Cancer Research|July 15, 2016
Anticoagulation, ferrotoxicity and the future of translational lung cancer researchLeo R Zacharski
Seminars in Thrombosis and Hemostasis|July 31, 2003
Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancerLeo R Zacharski
Thrombosis Research|September 27, 2003
Heparin treatment of malignancy: the case for clinical trials in colon cancerLeo R Zacharski
Idrugs : the Investigational Drugs Journal|July 24, 2004
Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, ItalyLeo R Zacharski
Anticancer Research|August 21, 2003
Low-molecular-weight heparin in oncologyLeo R Zacharski, James T Loynes
Expert Opinion on Pharmacotherapy|August 24, 2007
Venous thromboembolism prevention in cancer patients: the search for common antecedentsLeo R Zacharski, Cocav A Engman
Vascular and Endovascular Surgery|August 21, 2012
Iron reduction benefits: positive results from a "negative" prospective randomized controlled trialRalph G Depalma, Leo R Zacharski
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Cancer Letters|August 17, 2002
Anticoagulants in cancer treatment: malignancy as a solid phase coagulopathyLeo R Zacharski
Clinical Chemistry|September 13, 2014
Ferrotoxic disease: the next great public health challengeLeo R Zacharski
Clinical Chemistry|February 4, 2015
In replyLeo R Zacharski
Translational Lung Cancer Research|July 15, 2016
Anticoagulation, ferrotoxicity and the future of translational lung cancer researchLeo R Zacharski
Seminars in Thrombosis and Hemostasis|July 31, 2003
Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancerLeo R Zacharski
Thrombosis Research|September 27, 2003
Heparin treatment of malignancy: the case for clinical trials in colon cancerLeo R Zacharski
Idrugs : the Investigational Drugs Journal|July 24, 2004
Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, ItalyLeo R Zacharski
Anticancer Research|August 21, 2003
Low-molecular-weight heparin in oncologyLeo R Zacharski, James T Loynes
Expert Opinion on Pharmacotherapy|August 24, 2007
Venous thromboembolism prevention in cancer patients: the search for common antecedentsLeo R Zacharski, Cocav A Engman
Vascular and Endovascular Surgery|August 21, 2012
Iron reduction benefits: positive results from a "negative" prospective randomized controlled trialRalph G Depalma, Leo R Zacharski
Pageof 6